Skip to content
lifestyle.streetregister.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Abeona Therapeutics Inc.
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
November 9, 2026
Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
November 9, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 2, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
September 18, 2026
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
September 16, 2026
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
September 2, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2026
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
August 13, 2026
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
August 6, 2026
1
2
Next Page
→